Home / PD-1 / Recombinant Human PD-1 Fc Chimera Protein, CF

Recombinant Human PD-1 Fc Chimera Protein, CF

1086-PD 18 Citations 9 Reviews Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
1086-PD-050
1086-PD-01M
Graph showing bioactivity of Human PD-1 protein
1 Image
Product Details
Citations (18)
FAQs
Supplemental Products
Reviews (9)
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human PD-1 Fc Chimera Protein, CF Summary

The non-Fc, His-tagged PD-1 protein can be found here

PD-1 Protein His

Explore the full range of bioactive immune checkpoint proteins in addition to PD-1 Protein

I-O Proteins

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human PD-1 Fc Chimera is immobilized at 0.1 µg/mL (100 µL/well), Recombinant Human B7-H1/PD-L1 Fc Chimera (Catalog # 156-B7) binds with a typical ED50 of 0.15-0.75 μg/mL.
Source
Mouse myeloma cell line, NS0-derived human PD-1 protein
Human PD-1
(Leu25-Gln167)
Accession # Q15116		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus
Accession #
Q15116
N-terminal Sequence
Analysis
Leu25
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
42.6 kDa (monomer)
SDS-PAGE
60-70 kDa, reducing conditions

Product Datasheets

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

1086-PD

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Image

Bioactivity Bioactivity of Human PD-1 Protein View Larger

When Recombinant Human PD-1 Fc Chimera (Catalog # 1086-PD) is coated at 0.1 µg/mL, Recombinant Human B7-H1/PD-L1 Fc Chimera (156-B7) binds with a typical ED50 of 0.15-0.75 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: PD-1

PD-1 (Programmed Death-1 receptor), also known as CD279, is a receptor expressed on T cells responsible for modulating T cell activation. Like CTLA‑4, PD-1 is classified as an immune checkpoint inhibitory receptor. When PD-1 protein binds to PD-L1, it initiates a negative signaling cascade inhibiting activation of T cells. The cytoplasmic tail contains two tyrosine residues that form the immunoreceptor tyrosine-based inhibitory motif (ITIM) and immunoreceptor tyrosine-based switch motif (ITSM) that are important for mediating PD-1 signaling. Normally, PD-1 helps keep T cells from attacking other cells in the body. However, many cancers take advantage of this by expressing high amounts of PD-L1 allowing cancer cells to evade the body's own immune response. Blocking the PD-1:PD-L1 interaction has proven successful in treating many different cancer types.

PD-1 protein is type I transmembrane receptor belonging to the CD28 family of immune regulatory receptors (1). Other members of this family include CD28, CTLA‑4, ICOS, and BTLA (2-5). Mature human PD-1 consists of an extracellular region (ECD) with one immunoglobulin-like V‑type domain, a transmembrane domain, and a cytoplasmic region. The mature ECD of human PD-1 shares 61% amino acid sequence identity with mouse PD-1 ECD. PD-1 protein acts as a monomeric receptor and interacts in a 1:1 stoichiometric ratio with its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) (6, 7). PD‑1 is expressed on activated T cells, B cells, monocytes, and dendritic cells while PD-L1 expression is constitutive on the same cells and also on nonhematopoietic cells such as lung endothelial cells and hepatocytes (8, 9). Ligation of PD-L1 with PD-1 induces co-inhibitory signals on T cells promoting their apoptosis, anergy, and functional exhaustion (10). Thus, the PD-1:PD-L1 interaction is a key regulator of the threshold of immune response and peripheral immune tolerance (11).

References
  1. Ishida, Y. et al. (1992) EMBO J. 11:3887.
  2. Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
  3. Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203.
  4. Nishimura, H. and T. Honjo (2001) Trends Immunol. 22:265.
  5. Watanabe, N. et al. (2003) Nat. Immunol. 4:670.
  6. Zhang, X. et al. (2004) Immunity 20:337.
  7. Lázár-Molnár, E. et al. (2008) Proc. Natl. Acad. Sci. USA 105:10483.
  8. Nishimura, H. et al. (1996) Int. Immunol. 8:773.
  9. Keir, M.E. et al. (2008) Annu. Rev. Immunol. 26:677.
  10. Butte, M.J. et al. (2007) Immunity 27:111.
  11. Okazaki, T. et al. (2013) Nat. Immunol. 14:1212.
  12. Iwai, Y. et al. (2002) Proc. Natl. Acad. Sci. USA 99:12293.
  13. Nogrady, B. (2014) Nature 513:S10.
Long Name
Programmed Death-1
Entrez Gene IDs
5133 (Human); 18566 (Mouse); 301626 (Rat); 100533201 (Porcine); 486213 (Canine); 102123659 (Cynomolgus Monkey)
Alternate Names
CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2

Citations for Recombinant Human PD-1 Fc Chimera Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

18 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. MUC4-ErbB2 Oncogenic Complex: Binding studies using Microscale Thermophoresis
    Authors: M Liberelle, R Magnez, X Thuru, Y Bencheikh, S Ravez, C Quenon, AS Drucbert, C Foulon, P Melnyk, IV Seuningen, N Lebègue
    Sci Rep, 2019;9(1):16678.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
    Authors: M Passariell, AM D'Alise, A Esposito, C Vetrei, G Froechlich, E Scarselli, A Nicosia, C De Lorenzo
    Sci Rep, 2019;9(1):13125.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression
    Authors: W Wang, NM Chapman, B Zhang, M Li, M Fan, RN Laribee, MR Zaidi, LM Pfeffer, H Chi, ZH Wu
    Cancer Res., 2019;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
    Authors: N Zhang, Y Dou, L Liu, X Zhang, X Liu, Q Zeng, Y Liu, M Yin, X Liu, H Deng, D Song
    EBioMedicine, 2019;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  5. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer
    Authors: B Shao, CW Li, SO Lim, L Sun, YJ Lai, J Hou, C Liu, CW Chang, Y Qiu, JM Hsu, LC Chan, Z Zha, H Li, MC Hung
    Am J Cancer Res, 2018;8(9):1837-1846.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  6. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
    Authors: CW Li, SO Lim, EM Chung, YS Kim, AH Park, J Yao, JH Cha, W Xia, LC Chan, T Kim, SS Chang, HH Lee, CK Chou, YL Liu, HC Yeh, EP Perillo, AK Dunn, CW Kuo, KH Khoo, JL Hsu, Y Wu, JM Hsu, H Yamaguchi, TH Huang, AA Sahin, GN Hortobagyi, SS Yoo, MC Hung
    Cancer Cell, 2018;33(2):187-201.e10.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  7. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity
    Authors: H Wang, H Yao, C Li, H Shi, J Lan, Z Li, Y Zhang, L Liang, JY Fang, J Xu
    Nat. Chem. Biol., 2018;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
    Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
    JCI Insight, 2018;3(19):.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA (Capture)
  9. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
    Nature, 2016;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
    Nat Commun, 2016;7(0):12632.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  11. Rapid PD-L1 detection in tumors with PET using a highly specific peptide
    Authors: Samit Chatterjee
    Biochem. Biophys. Res. Commun, 2016;0(0):.
    Applications: Bioassay
  12. B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor.
    Authors: Yang Y, Wu K, Zhao E, Li W, Shi L, Xie G, Jiang B, Wang Y, Li R, Zhang P, Shuai X, Wang G, Tao K
    Oncol Lett, 2015;9(4):1833-1838.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
    Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
    PLoS ONE, 2014;9(12):e113396.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Standard)
  14. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
    Authors: Steidl C, Shah SP, Woolcock BW
    Nature, 2011;471(7338):377-81.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  15. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression.
    Authors: Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ, Hur DY
    J. Immunol., 2008;181(9):6158-69.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  16. Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis.
    Authors: Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK
    J. Neuroimmunol., 2007;193(1):149-55.
    Species: N/A
    Sample Types: N/A
    Applications: ELISA (Standard)
  17. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
    Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
    J. Immunol., 2006;177(12):8844-50.
  18. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
    Authors: Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W, Stankevich E, Pons A, Salay T, McMiller T, Gilson M, Wang C, Selby M, Taube J, Anders R, Chen L, Korman A, Pardoll D, Lowy I, Topalian S
    J Clin Oncol, 0;28(19):3167-75.
    Species: Human
    Sample Types: Serum
    Applications: ELISA (Capture)

FAQs

  1. The vial is supposed to contain lyophilized protein but it appears to be empty. Is there anything in it?

    • Pellets can be dislodged during shipping and become disbursed on the vial wall and in the cap. Centrifuge or tap the vial on the benchtop to return this material to the vial bottom. If this does not reveal a pellet, closely inspect the cone of the vial. Some pellets appear as only a tiny amount of material or as a transparent film due to the original buffer formulation. This is a normal appearance for many proteins. For example, if the product is originally lyophilized from a solvent such as acetonitrile or ethanol, and supplied carrier-free, you may not be able to detect the pellet with the naked eye. This does not mean the vial is empty. Reconstitute the vial as directed. After reconstitution, protein concentration can be tested with a spectrophotometer.

  2. What is the recommended method for reconstitution of a lyophilized protein or antibody?

    • Unless more specific directions are on the Certificate of Analysis provided with the product, we suggest the following procedure to ensure optimal recovery: 1. Allow the vial and reconstitution buffer to equilibrate to room temperature. 2. Briefly centrifuge the vial to ensure that all lyophiliate is collected at the bottom of the vial. 3. Add the amount of buffer required to achieve the concentration recommended on the product insert. 4. Allow the vial to reconstitute for 15-30 minutes at room temperature with gentle agitation, like on a rocker platform or rotating by hand.  Avoid vigorous shaking that can cause foaming and protein denaturation. 5. Aliquot into volumes greater than 20 μL and store as indicated on the product insert. If the vial exhibits flakes or particulates, mix the product for a couple of hours at room temperature and then at 4oC overnight. Contact Technical Service if product does not go into solution.  

       

  3. Are R&D Systems recombinant proteins and antibodies sterile?

    • Although the vials are bottled using aseptic techniques, heat-treated vials, and sterile stock solutions, they are not considered or guaranteed to be sterile. If sterile material is needed for an experiment, the material can be filtered through a 0.2 micron filter designed for use with biological fluids.

View all Proteins and Enzyme FAQs

Recombinant Proteins

Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF

156-B7
15 Citations
21 Reviews
1 Image
BA

Reconstitution Buffers

Reconstitution Buffer 1 (PBS)

RB01
2 Reviews

Reviews for Recombinant Human PD-1 Fc Chimera Protein, CF

Average Rating: 4.7 (Based on 9 Reviews)

5 Star
77.78%
4 Star
11.11%
3 Star
11.11%
2 Star
0%
1 Star
0%

Have you used Recombinant Human PD-1 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 06/26/2020
Application: In vitro bioactivity in cell culture
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 01/15/2020
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 01/12/2020
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 11/22/2019
Application: Binding assay/Protein-protein interaction

Cells expressing a negative control (left) or hPD-L1 mCherry (right) were treated with 0.25 ug of hPD-1 hIgG1. Cells were analyzed by flow cytometry with binding detected using an anti-human 488 secondary antibody.

Binding assay/Protein-protein interaction Recombinant Human PD-1 Fc Chimera Protein, CF 1086-PD
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 08/20/2018
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 12/08/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 11/03/2017
Application: Binding assay/Protein-protein interaction
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 04/21/2017
Application:
Recombinant Human PD-1 Fc Chimera Protein, CF
By Anonymous on 07/08/2016
Application: Binding assay/Protein-protein interaction

Sorry that I just rate the catalog based on my alike recombinant PD1 peptide. I have one question for the peptide. Owing the Ig like peptide with Fc fragment. So when we detect it binding to PDL1 on cell assay, it is difficult to get definite conclusion if it is PDL1 binding or others.
My protocol is as below:
-Cells with PDL1 high level was treated by PD1 like peptide,
-4degree 1hr
-collected and lysis
-WB by anti-IgG to Fc recognization.
Result: weak signal. you don't know if it is non-specific binding

***Bio-Techne Response: Thank you for reviewing our product. We are sorry to that that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.***